Tasigna (nilotinib) is a small molecule pharmaceutical. Nilotinib was first approved as Tasigna on 2007-10-29. It is used to treat myeloid leukemia accelerated phase and myeloid leukemia chronic-phase in the USA. It has been approved in Europe to treat bcr-abl positive chronic myelogenous leukemia. The pharmaceutical is active against tyrosine-protein kinase ABL1. In addition, it is known to target epithelial discoidin domain-containing receptor 1 and discoidin domain-containing receptor 2. Tasigna's patents are valid until 2032-04-07 (FDA).
|Indication||bcr-abl positive chronic myelogenous leukemia, myeloid leukemia accelerated phase, myeloid leukemia chronic-phase|
|Drug Class||Tyrosine kinase inhibitors|